Lexeo Therapeutics (LXEO) Other Operating Expenses (2023 - 2026)
Lexeo Therapeutics (LXEO) posted Other Operating Expenses of -$4.7 million for Q1 2026, down 168.35% sequentially from $6.9 million in Q4 2025, and up 62.52% YoY from -$2.9 million in Q1 2025.
Lexeo Therapeutics (LXEO) Other Operating Expenses (2023 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Other Operating Expenses for 4 years, with the latest figure at -$4.7 million in Q1 2026.
- Quarterly Other Operating Expenses rose 62.52% year-over-year to -$4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (up 60.41% YoY) and the FY2025 annual result came in at -$37.0 million, down 48.06% from the prior year.
- Other Operating Expenses slipped to -$4.7 million in Q1 2026 per LXEO's latest filing, from $6.9 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $53.1 million in Q4 2023 and troughed at -$12.6 million in Q1 2025.
- A 4-year average of $264300.0 and a median of -$4.5 million in 2024 frame the typical range for Other Operating Expenses.
- The widest YoY moves for Other Operating Expenses: up 158.39% in 2025, down 209.04% in 2025.
- Over 4 years, Other Operating Expenses stood at $53.1 million in 2023, then sank by 122.21% to -$11.8 million in 2024, then soared by 158.39% to $6.9 million in 2025, then tumbled by 168.35% to -$4.7 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$4.7 million, $6.9 million, and -$2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.95 Mn |
| Mar 31, 2026 | -4.71 Mn |
| Dec 31, 2025 | 6.89 Mn |
| Sep 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -12.24 Mn |
| Mar 31, 2025 | -12.57 Mn |
| Dec 31, 2024 | -11.80 Mn |
| Sep 30, 2024 | -4.34 Mn |
| Jun 30, 2024 | -3.96 Mn |
| Mar 31, 2024 | -4.89 Mn |
| Dec 31, 2023 | 53.13 Mn |